AAAAAA

   
Results: 1-8 |
Results: 8
SAFETY AND IMMUNOGENICITY OF AN HLA-BASED HIV ENVELOPE POLYVALENT SYNTHETIC PEPTIDE IMMUNOGEN
Authors: BARTLETT JA WASSERMAN SS HICKS CB DODGE RT WEINHOLD KJ TACKET CO KETTER N WITTEK AE PALKER TJ HAYNES BF
Citation: Ja. Bartlett et al., SAFETY AND IMMUNOGENICITY OF AN HLA-BASED HIV ENVELOPE POLYVALENT SYNTHETIC PEPTIDE IMMUNOGEN, AIDS, 12(11), 1998, pp. 1291-1300
THALIDOMIDE FOR THE TREATMENT OF ORAL APHTHOUS ULCERS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: JACOBSON JM GREENSPAN JS SPRITZLER J KETTER N FAHEY JL JACKSON JB FOX L CHERNOFF M WU AW MACPHAIL LA VASQUEZ GJ WOHL DA
Citation: Jm. Jacobson et al., THALIDOMIDE FOR THE TREATMENT OF ORAL APHTHOUS ULCERS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The New England journal of medicine, 336(21), 1997, pp. 1487-1493
ISOLATION AND CHARACTERIZATION OF HUMAN-PAPILLOMAVIRUS TYPE 6-SPECIFIC T-CELLS INFILTRATING GENITAL WARTS
Authors: HONG K GREER CE KETTER N VANNEST G PALIARD X
Citation: K. Hong et al., ISOLATION AND CHARACTERIZATION OF HUMAN-PAPILLOMAVIRUS TYPE 6-SPECIFIC T-CELLS INFILTRATING GENITAL WARTS, Journal of virology, 71(9), 1997, pp. 6427-6432
A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE
Authors: GORSE GJ KEEFER MC BELSHE RB MATTHEWS TJ FORREST BD HSIEH RH KOFF WC HANSON CV DOLIN R WEINHOLD KJ FREY SE KETTER N FAST PE
Citation: Gj. Gorse et al., A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE, The Journal of infectious diseases, 173(2), 1996, pp. 330-339
PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY, IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: WOLFE EJ CAVACINI LA SAMORE MH POSNER MR KOZIAL C SPINO C TRAPNELL CB KETTER N HAMMER S GAMBERTOGLIO JG
Citation: Ej. Wolfe et al., PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY, IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, Clinical pharmacology and therapeutics, 59(6), 1996, pp. 662-667
PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY FOR THE TREATMENT OF HIV-INFECTION - A PHASE-I STUDY
Authors: WOLFE EJ CAVACINI LA POSNER MR SAMORE MH SPINO C KETTER N TRAPNELL C HAMMER S GAMBERTOGLIO JG
Citation: Ej. Wolfe et al., PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY FOR THE TREATMENT OF HIV-INFECTION - A PHASE-I STUDY, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 143-143
PHASE I II TRIALS OF CANDIDATE HIV-1 VACCINES
Authors: FAST P KETTER N WALKER MC WESCOTT SL SCHULTZ AM
Citation: P. Fast et al., PHASE I II TRIALS OF CANDIDATE HIV-1 VACCINES, AIDS research and human retroviruses, 10, 1994, pp. 190000049-190000049
PHASE-I AND PHASE-II TRIALS OF CANDIDATE-PREVENTIVE HIV VACCINES
Authors: KETTER N FAST P WALKER MC WESCOTT SL SCHULTZ AM
Citation: N. Ketter et al., PHASE-I AND PHASE-II TRIALS OF CANDIDATE-PREVENTIVE HIV VACCINES, Transfusion, 34(8), 1994, pp. 731-731
Risultati: 1-8 |